{"id":"NCT01313494","sponsor":"AstraZeneca","briefTitle":"A Chronic Obstructive Pulmonary Disease (COPD) Trial Investigating Roflumilast on Safety and Effectiveness in China, Hong Kong and Singapore:","officialTitle":"A 6-month, Double-blind, Randomised, Multicenter, Multinational Trial to Investigate the Effect of 500 µg Roflumilast Tablets Once Daily Versus Placebo on Pulmonary Function in Patients With COPD. The ACROSS Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-03","primaryCompletion":"2012-05","completion":"2012-05","firstPosted":"2011-03-11","resultsPosted":"2013-08-02","lastUpdate":"2017-02-01"},"enrollment":626,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["COPD"],"interventions":[{"type":"DRUG","name":"Roflumilast","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Salbutamol","otherNames":[]}],"arms":[{"label":"Roflumilast","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The aim of this trial is to determine the efficacy, safety and tolerability of 500 µg Roflumilast tablets once daily in patients with COPD in China, Hong Kong, and Singapore.","primaryOutcome":{"measure":"Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)","timeFrame":"Baseline to Week 24","effectByArm":[{"arm":"Roflumilast","deltaMin":0.049,"sd":0.009},{"arm":"Placebo","deltaMin":-0.022,"sd":0.009}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":5},"locations":{"siteCount":15,"countries":["China","Hong Kong","Singapore"]},"refs":{"pmids":["24135893"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":62,"n":315},"commonTop":["Chronic obstructive pulmonary disease","Nasopharyngitis","Upper respiratory tract infection","Diarrhoea","Decreased appetite"]}}